PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
39.38
-0.50 (-1.25%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close39.88
Open39.93
Bid39.07 x 4000
Ask39.10 x 1000
Day's Range38.42 - 39.93
52 Week Range34.37 - 46.47
Volume47,722,983
Avg. Volume24,613,045
Market Cap218.63B
Beta (3Y Monthly)0.59
PE Ratio (TTM)21.10
EPS (TTM)1.87
Earnings DateApr 30, 2019
Forward Dividend & Yield1.44 (3.39%)
Ex-Dividend Date2019-01-31
1y Target Est44.36
Trade prices are not sourced from all markets
  • The Top 10 Biotechnology Companies (JNJ, ROG.VX)
    Investopedia5 hours ago

    The Top 10 Biotechnology Companies (JNJ, ROG.VX)

    Learn how the marriage of science and technology is changing the world of medicine and creating some of the largest multinational biotechnology corporations.

  • MarketWatch10 hours ago

    Pfizer, Lilly shares decline as osteoarthritis drug misses goals in study

    Shares of drug makers Pfizer Inc. and Eli Lilly & Co. declined in the extended session Thursday after the companies said a clinical study of an osteoarthritis drug didn't meet certain goals. Pfizer shares declined 1% after hours, following a 1.3% decline to close at $39.38 in the regular trading session. Lilly shares fell 1.9% after hours, following a 1.1% close lower at $115.20. The companies said that a late-stage study of their drug tanezumab at 5 mg did not show a statistically significant improvement in overall osteoarthritis symptoms compared with nonsteroidal anti-inflammatory drugs. A 2.5 mg dose did not show a statistically significant improvement in pain, physical function or patients' overall assessment, the companies said. "We are analyzing these findings in the context of the recent Phase 3 results as we assess potential next steps for tanezumab," said Ken Verburg, Pfizer's tanezumab development team leader, in a statement. "We plan to review the totality of data from our clinical development program for tanezumab with regulatory authorities."

  • Reuters10 hours ago

    Lower dose of Pfizer-Lilly painkiller misses main goals in late stage study

    A lower dose of non-opioid painkiller developed by Pfizer Inc and Eli Lilly and Co failed to meet main goals in a late-stage study in patients with moderate-to-severe osteoarthritis of the hip or knee, the companies said on Thursday. The drug, tanezumab, belongs to a new category of pain medications that target nerve growth factor, a protein involved in the growth of nerve cells, and has been touted as a potential blockbuster. The study tested the treatment in two doses, 2.5 mg and 5 mg, comparing the long-term joint safety and effectiveness at the end of 16 weeks with painkillers that are normally prescribed to patients.

  • Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
    Zacks11 hours ago

    Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know

    Pfizer (PFE) closed at $39.38 in the latest trading session, marking a -1.25% move from the prior day.

  • Worsening Health-Care Rout Wipes Out $150 Billion in Four Days
    Bloomberg11 hours ago

    Worsening Health-Care Rout Wipes Out $150 Billion in Four Days

    About $150 billion of market value was erased from companies in the S&P 500 Health Care Index in the four days through Thursday, when markets closed for the holiday weekend. “This is third-worst that I’ve seen probably in the last 10 years,” Christian Fay, who helps manage $3.6 billion at BNP Paribas Asset Management, said in a telephone interview.

  • Pfizer and Lilly Announce Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis
    Business Wire11 hours ago

    Pfizer and Lilly Announce Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis

    Pfizer Inc. (PFE) and Eli Lilly and Company (LLY) today announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg. The objective of the study was to compare the long-term joint safety and 16-week efficacy of tanezumab relative to nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with moderate-to-severe osteoarthritis (OA) of the hip or knee. The tanezumab 5 mg treatment arm met two of the three co-primary efficacy endpoints, demonstrating a statistically significant improvement in pain and physical function compared to NSAIDs at the 16-week analysis, while patients’ overall assessment of their OA was not statistically different than NSAIDs. Patients who received tanezumab 2.5 mg did not experience a statistically significant improvement in pain, physical function or patients’ overall assessment of their OA at 16 weeks compared to NSAIDs.

  • Business Wire14 hours ago

    Pfizer Invites Public to Listen to Webcast of April 25 Annual Meeting of Shareholders

    Pfizer Inc. invites investors and the general public to listen to an audio webcast of the Annual Meeting of Shareholders at 9:00 a.m. Eastern Daylight Time on Thursday, April 25, 2019. To pre-register and access the live audio webcast, visit https://investors.pfizer.com/proxy and click on the “Meeting Webcast” button. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.

  • Clovis Focuses on Rubraca Label Expansion, Competition Stiff
    Zacks17 hours ago

    Clovis Focuses on Rubraca Label Expansion, Competition Stiff

    Although sales of Clovis' (CLVS) Rubraca improved in the fourth quarter of 2018, the drug may face significant competition going forward. Clovis is also evaluating Rubrca for other cancer indications.

  • Can Q1 Earnings Lift Healthcare ETFs Higher?
    Zacks17 hours ago

    Can Q1 Earnings Lift Healthcare ETFs Higher?

    With negative earnings revisions, the healthcare sector is expected to witness earnings growth of 1.8% in the first quarter, suggesting smooth trading for healthcare ETFs.

  • Here Are the Key Takeaways From J&J's Q1 Earnings Report
    Zacks18 hours ago

    Here Are the Key Takeaways From J&J's Q1 Earnings Report

    Let's have a look at some of the highlights of J&J's (JNJ) first-quarter 2019 results.

  • Wave Life Sciences Plunges After DMD Study Data Readout
    Zacks2 days ago

    Wave Life Sciences Plunges After DMD Study Data Readout

    Wave Life Sciences (WVE) announces final safety data from a phase I DMD study evaluating suvodirsen and provides design update for phase II/III stage development of the candidate.

  • Investing.com2 days ago

    Pfizer Falls 3%

    Investing.com - Pfizer (NYSE:PFE) fell by 3.02% to trade at $39.69 by 13:51 (17:51 GMT) on Wednesday on the NYSE exchange.

  • 5 Healthcare Stocks to Watch If America Chooses a Single-Payer System
    InvestorPlace3 days ago

    5 Healthcare Stocks to Watch If America Chooses a Single-Payer System

    Even for the brightest among us, our current healthcare system is a convoluted mess that's difficult to fully understand. With terms like HMOs, PPOs and PFPMs, searching for the right coverage is often as desirable as doing your taxes. However, a political movement to simplify the system has serious implications for you and your portfolio (via healthcare stocks).Earlier this week, Senator Bernie Sanders explained his ambitious plan for a single-payer healthcare system. Broadly, what this entails is that all Americans will enjoy comprehensive health coverage. Under his "Medicare for All Act," patients won't have to pay out of pocket for doctor visitations. It has raised eyebrows because the proposal is considerably more generous than other single-payer countries.Even more startling for both supporters and opponents, Sanders' plan has generated significant support. In particular, presidential candidates Elizabeth Warren, Cory Booker, Kamala Harris and Kirsten Gillibrand cosponsored the bill. With momentum rising, so too has the importance for healthcare stocks to watch.InvestorPlace - Stock Market News, Stock Advice & Trading TipsOne of the striking components of Sanders' plan is its scope. If it passes, all invoices will eventually go to the federal government. Theoretically, this approach does away with some of the volatile pricing imposed within the current system. But such pricing changes would severely impact healthcare stocks.Another sticking point regarding this comprehensive proposal is a possible existential crisis. In many ways, healthcare stocks exist because our broader medical umbrella is so convoluted. Plus, pharmaceuticals can radically hike drug prices, knowing that insurers and patients have little recourse. * 7 Stocks to Buy for Spring Season Growth Of course, paying for a new system would require a substantial tax influx. Sanders hasn't provided a convincing financial plan to accommodate his bill. Nevertheless, the current political environment suggests a change is coming. Here are five healthcare stocks to watch, just in case. UnitedHealth Group (UNH)Source: Shutterstock On Thursday, shares of UnitedHealth Group (NYSE:UNH) tumbled over 4%, and I can't say that I'm surprised. Sure, the commonly cited explanation for why UNH stock took a hit was an analyst downgrade. But the reality is that among healthcare stocks to watch, insurance providers suffer the most risk.Naturally, the Medicare for All Act weighs heavily on UNH stock. Insurers thrive on both the complexity of our healthcare system and the necessity for it. Going without insurance just isn't smart, considering the likelihood of a catastrophic event or disease. According to a shocking BBC report last year, cancer is rising everywhere, including in developed nations.Moreover, fighting that awful disease isn't cheap, with average treatments running well into six digits. The threat of financial ruin is enough for people to run to insurance companies. But with government-endorsed mandated coverage, it's unclear how for-profit insurers like UNH stock can thrive. Cigna (CI)Source: Shutterstock Also on Thursday, shares of Cigna (NYSE:CI) fell sharply, losing 2.5%. Again, I'm not surprised. Compared to other healthcare stocks to watch, CI stock faces an existential threat. If the Medicare for All Act passes, it has severe implications for the insurance company.As we discussed, Sanders' plan is incredibly comprehensive. In his vision of a covered America, no one reaches into their wallets. Whether you're seeing a doctor, getting your teeth cleaned at the dentist's office, or trying on a new pair of eyeglasses, sticker shock in this arena will be obsolete. * 10 S&P 500 Stocks to Weather the Earnings Storm Of course, the problem is that CI stock thrives on this sticker shock. When you cut through all the corporate BS, you realize that the insurance industry prospers on fear. But a government-mandated coverage plan eliminates that fear with a safety net. Thus, I'm currently hesitant on Cigna, and other insurance-related healthcare stocks. Pfizer (PFE)Source: Kojach Via FlickrAlthough insurance companies present an easy target in light of recent political developments, pharmaceuticals can't dodge the bullet, either. Investors and especially current shareholders of Pfizer (NYSE:PFE) should adopt a very cautious stance. On Thursday, PFE stock dipped more than 1%.As with the first two healthcare stocks to watch, Pfizer's pensive trading isn't surprising. In prior generations, a rising tide lifted all boats. But in the next few years, a receding tide could strand everyone. That might be the case for PFE stock, and similar rivals in the pharmaceutical space.As the controversy surrounding the "pharma bro" incident revealed, pharmaceuticals can get away with charging ridiculous prices. But with the Medicare for All Act, that type of predatory behavior -- or even robust capitalism -- stops. When you have to answer to the federal government, suddenly, everyone plays nice.That's great for patients, but not so much for PFE stock. Boston Scientific (BSX)Source: Boston Scientific Ordinally, I wouldn't issue a cautionary note on Boston Scientific (NYSE:BSX). As one of the world's premiere medical-equipment providers, BSX stock represents a life-saving investment. Plus, shares have generally performed well following the aftermath of the Great Recession.Unfortunately, that might change in the coming years, especially if the Medicare for All Act passes. Similar to the plight of other medical stocks to watch, Boston Scientific absorbed a noticeable 1% decline on Thursday. That's just the beginning if the worst-case scenario occurs. * 10 Dividend Growth Stocks You Can't Miss Primarily, BSX stock will essentially lose out on a free market. Instead, a government-imposed network will dictate product pricing and other core details. Essentially, this eliminates the profit motive for Boston Scientific. Since many developed countries have some sort of single-payer system, BSX must cope with the loss of a viable partner. HCA Healthcare (HCA)Source: Shutterstock On surface level, HCA Healthcare (NYSE:HCA) should be one of the healthcare stocks to watch…for a positive reason. Following the end of the Obama administration, Gallup reported a conspicuous rise in the number of uninsured Americans. But under Medicare for All, the insured will likely represent a surge in demand for HCA stock.That's a strong benefit, but it's probably not a net benefit. I say this because the markets really punished HCA stock on Thursday, dropping it down nearly 3%. The most common explanation is that the rest of the sector was also volatile. If other segments within the healthcare industry falls, so too will HCA.But the overriding factor behind the single-payer proposal is big government. So even if the uninsured flock to hospitals and clinics, they can't adopt capitalistic pricing. Instead, the feds will oversee everything, ensuring everyone has access to equal and "fair" healthcare.It's a great deal for patients, but not so much for hospitals, or anyone in this industry for that matter.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * FAANNG Stocks, Ranked From Cheapest to Most Expensive * 7 Stocks With a Lot on the Line This Earnings Season * 7 Marijuana Companies: Which Pot Stocks Should You Buy? Compare Brokers The post 5 Healthcare Stocks to Watch If America Chooses a Single-Payer System appeared first on InvestorPlace.

  • J&J (JNJ) Beats on Q1 Earnings, Ups 2019 Sales Growth View
    Zacks3 days ago

    J&J (JNJ) Beats on Q1 Earnings, Ups 2019 Sales Growth View

    J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2019 and raises 2019 guidance for operational sales and adjusted operational EPS growth. Shares up in pre-market trading.

  • These 2 health-care giants could take down the ETFs in their sector, says investor
    CNBC3 days ago

    These 2 health-care giants could take down the ETFs in their sector, says investor

    Health-care stocks are under pressure, and the sector's fate rests on two of the space's most well-known names, says one expert.

  • Seeking $86 million IPO, this Peninsula company is betting common bacteria plays role in Alzheimer's
    American City Business Journals4 days ago

    Seeking $86 million IPO, this Peninsula company is betting common bacteria plays role in Alzheimer's

    The South San Francisco company is putting its IPO where its mouth is — hoping to take its lead drug, targeting a tooth-loss-causing bacteria that migrates from the mouth to the brain, into a Phase II/III clinical trial soon.

  • Analyzing Recent Regulatory Approvals for Pfizer’s Oncology Drugs
    Market Realist4 days ago

    Analyzing Recent Regulatory Approvals for Pfizer’s Oncology Drugs

    Pfizer or AstraZeneca: Which Is a Better Pick in April?(Continued from Prior Part)Lorbrena’s approvalOn November 2, Pfizer (PFE) issued a press release announcing the FDA’s approval of Lorbrena, a third-generation TKI (tyrosine kinase

  • J&J's Erdafitinib Gets FDA Approval for Urothelial Cancer
    Zacks4 days ago

    J&J's Erdafitinib Gets FDA Approval for Urothelial Cancer

    FDA grants approval to J&J's (JNJ) erdafitinib for metastatic urothelial cancer, a type of bladder cancer. This is J&J's second FDA approval for a new drug in less than two months

  • Xtandi: A Key Oncology Pillar in 2019
    Market Realist4 days ago

    Xtandi: A Key Oncology Pillar in 2019

    Pfizer or AstraZeneca: Which Is a Better Pick in April?(Continued from Prior Part)Xtandi’s growth trends According to Pfizer’s (PFE) fourth-quarter earnings conference call, Xtandi is a pillar of the company’s oncology business. In 2018, Pfizer

  • Why Ibrance Is a Major Growth Driver for Pfizer
    Market Realist4 days ago

    Why Ibrance Is a Major Growth Driver for Pfizer

    Pfizer or AstraZeneca: Which Is a Better Pick in April?(Continued from Prior Part)Recent Ibrance approval On April 4, Pfizer (PFE) issued a press release announcing the FDA’s approval of its leading CDK4/6 (cyclin-dependent kinase 4/6) inhibitor

  • The 3 Greatest Risks Pfizer Faces
    Motley Fool5 days ago

    The 3 Greatest Risks Pfizer Faces

    Here's what could get in the way of the big pharma company's future success.

  • Business Wire6 days ago

    Pfizer Announces Presentation of Data from a Phase 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older

    The U.S. FDA awarded Breakthrough Therapy Designation for this potential indication based on these Phase 2 data

  • PFE or AZN: Comparing Their Earnings Growth in 2019
    Market Realist7 days ago

    PFE or AZN: Comparing Their Earnings Growth in 2019

    Pfizer or AstraZeneca: Which Is a Better Pick in April?(Continued from Prior Part)Earnings guidance On its fourth-quarter earnings conference call, Pfizer (PFE) said that it expected its 2019 adjusted diluted EPS to be $2.82–$2.92, which doesn’t

  • What Are Analysts Recommending for PFE and AZN?
    Market Realist7 days ago

    What Are Analysts Recommending for PFE and AZN?

    Pfizer or AstraZeneca: Which Is a Better Pick in April?Stock price movementsOn April 11, Pfizer (PFE) closed at $42.27, 1.08% lower than its previous closing price, 22.99% higher than its 52-week low of $34.37, and 9.04% below its 52-week high of

  • Dow 30 Stock Roundup: Procter & Gamble Hikes Dividend, Boeing Q1 Commercial Deliveries Fall
    Zacks7 days ago

    Dow 30 Stock Roundup: Procter & Gamble Hikes Dividend, Boeing Q1 Commercial Deliveries Fall

    The index traversed a lackluster trading week as investors looked toward first-quarter earnings numbers for direction.